BTIG raised the firm’s price target on GE HealthCare (GEHC) to $103 from $99 and keeps a Buy rating on the shares following quarterly results. The firm believes “green shoots” appear to be emerging in China for the company as Orders grew and looking ahead to the first half of 2025, BTIG expects healthy Order growth given easier comps, consistent with its upgrade thesis ahead of Q3 2024 results. Regardless of the top-line dynamics, GE HealthCare deserves credit for the improved profitability being shown on the P&L, the firm argues. Overall, BTIG thinks there is a lot for investors to look forward to based on this print.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- Early notable gainers among liquid option names on February 13th
- Morning Movers: Molson Coors rises following earnings, Deere falls
- GE HealthCare sees FY25 free cash flow ‘at least’ $1.75B
- GE HealthCare reports Q4 adjusted EPS $1.45, consensus $1.26
- GE HealthCare sees FY25 adjusted EPS $4.61-$4.75, consensus $4.65